Abstract:Research on CAR T cells has achieved enormous progress in recent years. After the impressive results obtained in relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell lymphomas, two constructs, tisagenlecleucel and axicabtagene ciloleucel, were approved by FDA. The role of CAR T cells in the treatment of B-cell disorders, however, is rapidly evolving. Ongoing clinical trials aim at comparing CAR T cells with standard treatment options and at evaluating their efficacy earlier in the disease course. The use of CAR T cells is still limited by the risk of relevant toxicities, most commonly cytokine release syndrome and neurotoxicity, whose management has nonetheless significantly improved. Some patients do not respond or relapse after treatment, either because of poor CAR T-cell expansion, lack of anti-tumor effects or after the loss of the target antigen on tumor cells. Investigators are trying to overcome these hurdles in many ways: by testing constructs which target different and/or multiple antigens or by improving CAR T-cell structure with additional functions and synergistic molecules. Alternative cell sources including allogeneic products (off-the-shelf CAR T cells), NK cells, and T cells obtained from induced pluripotent stem cells are also considered. Several trials are exploring the curative potential of CAR T cells in other malignancies, and recent data on multiple myeloma and chronic lymphocytic leukemia are encouraging. Given the likely expansion of CAR T-cell indications and their wider availability over time, more and more highly specialized clinical centers, with dedicated clinical units, will be required. Overall, the costs of these cell therapies will also play a role in the sustainability of many health care systems. This review will focus on the major clinical trials of CAR T cells in B-cell malignancies, including those leading to the first FDA approvals, and on the new settings in which these constructs are being tested. Besides, the most promising approaches to improve CAR T-cell efficacy and early data on alternative cell sources will be reviewed. Finally, we will discuss the challenges and the opportunities that are emerging with the advent of CAR T cells into clinical routine.

CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them

CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Transforming CLL Management with Immunotherapy: Investigating the Potential of CAR T-Cells and Bispecific Antibodies

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia

Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease

CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Progress in clinical application of chimeric antigen receptor-T cells for the refractory and relapsed B-cell leukemia

Targeting chronic lymphocytic leukemia with B-cell activating factor receptor CAR T cells

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

CAR T cell therapy for B-cell lymphomas

CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS

CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms

CAR-T Cells and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/refractory B-cell Acute Lymphoblastic Leukemia

Current Status of CAR T Cell Therapy for Leukemias

Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes

Current state of CAR-T therapy for T-cell malignancies

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia